

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-39 (cancelled).

40 (currently amended). A disease associated, antigen activated cytotoxic T-cell line, wherein the cells have exceeded ~~or have an expected~~ a life-span of at least 40 PD.

41-59 (cancelled).

60 (currently amended). A T-cell line according to claim 40 wherein the functional profile of the ~~cytotoxic T cells essentially corresponds to the functional profile of the initial cytotoxic T cells of the tissue sample~~ is not substantially altered during continuous growth.

61 (currently amended). A T-cell line according to claim 40 obtained by culturing a tissue sample from a human patient comprising ~~normal~~ disease associated antigen activated cytotoxic T-cells in the presence of at least two factors which promote T-cell growth and one or more additional compounds promoting cytotoxic T cell selection and expansion exceeding 40 PD.

62 (previously presented). A T-cell line according to claim 61, wherein the factors which promote cytotoxic T-cell growth are selected from the group consisting of cytokines which promote cytotoxic T-cell growth.

63 (currently amended). A T-cell line according to claim 62, wherein the cytokines are selected from the group consisting of IL-2, IL-4, IL-7, IL-9, IL-10, IL-15, IL-16 and IL-12 ~~functionally similar cytokines.~~

64 (previously presented). A T-cell line according to claim 63, wherein a combination of at least one of IL-2 or IL-15; and at least one of IL-4 or IL-7 or IL-9 is used.

65 (previously presented). A T-cell line according to claim

64, wherein a combination of IL-2 and IL-4 is used.

66 (previously presented). A T-cell line according to claim 62, wherein each of the cytokines is used in a concentration of at least 1 nM.

67 (previously presented). A T-cell line according to claim 66, wherein each of the cytokines is used in a concentration of at least 2.5 nM.

68 (previously presented). A T-cell line according to claim 61, wherein the tissue sample is selected from the group consisting of a biopsy, sputum, a swab, a gastric lavage, a bronchial lavage, an intestinal lavage, or another body fluid.

69 (currently amended). A T-cell line according to claim 68, wherein the tissue sample is ~~a body fluid~~ selected from the group consisting of spinal, pleural, pericardial, synovial, blood and bone marrow body fluids.

70 (previously presented). A T-cell line according to claim 60, wherein the cytotoxic T-cells are cells having a CD8+ phenotype.

71 (currently amended). A T-cell line according to claim 60, wherein the cytotoxic T-cells are tumour infiltrating lymphocytes (TIL) ~~or cells having similar properties~~.

72 (currently amended). A cytotoxic T-cell line according to claim 61, wherein the one or more additional compounds are selected from the group consisting of GM-CSF, caspase inhibitors, Z-VAD, α -CD95, IL-10, IL-12, and IL-16, ~~and functionally similar compounds~~.

73 (previously presented). A cytotoxic T-cell line according to claim 60, wherein the disease is of neoplastic origin.

74 (previously presented). A cytotoxic T-cell line according to claim 73, wherein the disease is selected from the group consisting of malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the uterus, prostatic cancer,

hepatic carcinoma, and cutaneous lymphoma.

75 (currently amended). ~~An immunological~~ A pharmaceutical composition comprising disease associated antigen activated cytotoxic T-cells ~~isolated from the cytotoxic T-cell line~~ according to claim 40 and one or more excipients selected from the group consisting of water, saline, dextrose, glycerol, and ethanol.

76 (currently amended). ~~An immunological~~ A pharmaceutical composition according to claim 75, wherein the T-cells are reactivated in the presence of one or more reactivating antigens.

77 (currently amended). ~~An immunological~~ A pharmaceutical composition according to claim 76, wherein each reactivating antigen or antigen is selected from the group consisting of disease associated antigens, alloantigens and super-antigens.

78 (currently amended). ~~An immunological~~ A pharmaceutical composition according to claim ~~17~~ 77, wherein each reactivating antigen is a superantigen selected from the group consisting of SEA, SEB, SEC, SED, SEE, TSST, Streptococcus pyogenes enterotoxin A, B and C, and Mycoplasma arthritidis antigen.

79 (currently amended). ~~An immunological~~ A pharmaceutical composition according to claim 75, wherein the T-cells are incapable of further cell division.

80 (previously presented). A method of obtaining a cytotoxic T-cell line according to claim 40 comprising

- (a) obtaining a tissue sample comprising disease associated, antigen activated cytotoxic T cells from a human patient, and
- (b) culturing said tissue sample in the presence of at least two factors which promote T-cell growth and one or more additional compounds promoting cytotoxic T-cell selection and expansion exceeding 40 PD.

81 (currently amended). A method according to claim 80 wherein the functional profile of the cytotoxic T-cells

~~essentially correspond to the initial functional profile of the cytotoxic T-cells of the tissue sample~~ is not substantially altered during continuous culture.

82 (currently amended). A method for treatment of neoplastic diseases comprising administering ~~an immunological~~ a pharmaceutical composition comprising an immunologically effective amount of disease associated antigen activated cytotoxic T-cells isolated from the continuous T-cell line according to claim 40.

83 (previously presented). A method according to claim 82 wherein the functional profile of the cytotoxic T-cells essentially corresponds to the initial functional profile of the cytotoxic T-cells of the tissues sample.

84 (cancelled).

85 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 60 PD.

86 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 100 PD.

87 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 150 PD.

88 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 200 PD.

89 (new). A cell line according to claim 40 wherein the cells have exceeded a lifespan of 50 PD.

90 (new). A cell line according to claim 40 wherein the cells have exceeded a lifespan of 60 PD.